Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
PaperCitations, authors & open-access status
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 170 citations, 2024 year and hybrid oa status.
170
Citations
2024
Year
hybrid
OA Status